Mark-David Levin

Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel et al. · Haematologica · 2018 · 262 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

Marinus H. J. van Oers, Kazimierz Kuliczkowski, Lukáš Smolej et al. · The Lancet Oncology · 2015 · 112 citations

Medicine, Hematology, Oncology +15

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Katja Weisel, Andrew Spencer, Suzanne Lentzsch et al. · Journal of Hematology & Oncology · 2020 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

Rowan Kuiper, Sonja Zweegman, Mark van Duin et al. · Blood Advances · 2020 · 34 citations · Full text

Medicine, Oncology, Chemotherapy +15

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Lene Kongsgaard Nielsen, Claudia A.M. Stege, Birgit I. Lissenberg‐Witte et al. · Haematologica · 2019 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +17